Amrad Corporation Limited

Julie Ann King

Nicos Anthony Nicola

David P Gearing

Donald Metcalf

Nicholas Martin Gough

Richard John Simpson

Douglas James Hilton

Tracy Ann Willson

Edouard C Nice

David Paul Gearing

The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA and suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

Leukaemia inhibitory factor

The invention provides a recombinant or synthetic receptor or a derivative thereof, for granulocyte-macrophage colony-stimulating factor (GM-CSF). The GM-CSF receptor is useful, inter alia, in the treatment or diagnosis of GM-CSF-related diseases, and in the screening of agonists and antagonists of GM-CSF receptors. The invention further provides antibodies directed against GM-CSF receptor or derivatives thereof, and pharmaceutical compositions comprising either the GM-CSF receptor, the receptor derivative, or an antibody thereto, and methods of using thereof.

Antibodies which bind granulocyte-macrophane colony-stimulating factor

The present invention provides isolated DNA molecules encoding human and murine LIF, and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibody thereto.

Granulocyte-macrophage colony-stimulating factor receptor and

The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibodies thereto.

Growing community of inventors

Seattle, WA, United States of America

Julie Ann King